Compare OPBK & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPBK | OTLK |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.2M | 249.6M |
| IPO Year | 2018 | 2016 |
| Metric | OPBK | OTLK |
|---|---|---|
| Price | $15.70 | $0.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $16.50 | $2.50 |
| AVG Volume (30 Days) | 34.4K | ★ 13.7M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.73% | N/A |
| EPS Growth | 23.74 | ★ 55.91 |
| EPS | ★ 0.48 | N/A |
| Revenue | $3,204,000.00 | ★ $8,146,123.00 |
| Revenue This Year | $16.07 | $1,430.98 |
| Revenue Next Year | $11.60 | $173.23 |
| P/E Ratio | $32.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.41 | $0.16 |
| 52 Week High | $16.80 | $3.39 |
| Indicator | OPBK | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 38.39 |
| Support Level | $13.76 | $0.26 |
| Resistance Level | N/A | $1.83 |
| Average True Range (ATR) | 0.59 | 0.20 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 48.94 | 13.84 |
OP Bancorp operates its commercial community banking activities through Open Bank its wholly owned banking subsidiary. It provides commercial banking services to small and medium-sized businesses, their owners, and retail customers, with a focus on the Korean-American community. The bank currently operate twelve full service branches: nine branches across Los Angeles and Orange Counties in California, as well as one branch each in Santa Clara, California; Carrollton, Texas; and Las Vegas, Nevada. Additionally, it maintains five loan production offices located in Pleasanton, California; Atlanta, Georgia; Aurora, Colorado; Lynnwood, Washington; and Fairfax, Virginia. Substantially all its business activities are conducted through the Bank.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.